drugset / Trial / NCT06119789
Precision Cancer Therapy in Rare Cancers
Phase 2
Recruiting
96 enrolled
Oslo University Hospital
Haukeland University Hospital · collabHelse Fonna · collabHelse Forde · collabHelse Nord-Trøndelag HF · collabHelse Stavanger HF · collabMøre og Romsdal Hospital Trust · collabNordlandssykehuset HF · collabSorlandet Hospital HF · collabSt. Olavs Hospital · collabSykehuset Innlandet HF · collabSykehuset Ostfold · collabThe Hospital of Vestfold · collabUniversity Hospital of North Norway · collab
NaSingle-groupOpen-labelTreatment
Summary
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Timeline
- Start
- 2025-03-20
- Primary completion
- 2033-11-30
- Completion
- 2036-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Subject | Trametinib | Small molecule | — | — |